Alfred Hospital
Melbourne, Victoria, 3004, Australia
NCT Number: NCT01906931
People with interstitial lung disease (ILD) are frequently prescribed ambulatory oxygen, to increase oxygen levels in the blood during daily activities. The best way of delivering this type of oxygen has not been established. The aim of this study is to compare two devices for delivering oxygen in people with interstitial lung disease - the traditional method using portable cylinders and a newer method using a portable concentrator. The investigators hypothesise that oxygen levels during exercise will be significantly higher when using a portable cylinder, but this difference will be small.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Melbourne, Victoria, 3004, Australia
Exercise-induced hypoxaemia (EIA) is very common in individuals with ILD, due to progressive lung fibrosis which results in impaired gas exchange. It is common for people with EIA to be prescribed ambulatory oxygen, in order to normalize oxyhaemoglobin saturation, improve oxygen delivery to the tissues and relieve breathlessness during daily activities.
Ambulatory oxygen is traditionally delivered via a refillable portable oxygen cylinder containing compressed gaseous oxygen. More recently, portable oxygen concentrators (POCs) have emerged as a solution to the problem of finite cylinder life and to improve portability. Because a concentrator is constantly extracting oxygen from air, oxygen supply can continue as long as the battery is charged. This is typically around eight hours, but POCs can be recharged from an AC or DC power source. Portable oxygen concentrators usually weigh around 3.5kg, which is significantly lighter than oxygen cylinders, and are much easier to maneuver. However, there are some theoretical disadvantages to POCs. Like all concentrators, they do not deliver 100% oxygen. Concentrations typically range from 85-95%, depending on the flow rate. Differences in pulse timing and peak pulse flow between POCs may affect the fraction of inspired oxygen (FiO2) that is delivered. However, the clinical implications of these differences have not been documented.
The aim of this study is to compare the effects of ambulatory oxygen delivered during exercise using the EverGo POC to ambulatory oxygen delivered with a standard portable cylinder in individuals with ILD. We hypothesise that oxyhaemoglobin saturation during exercise will be significantly higher when using a portable cylinder, but this difference will not be clinically important.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Respironics EverGo portable oxygen concentrator on setting 6
Other names: Respironics EverGo portable oxygen concentrator
Portable oxygen cylinder at flow rate 5 Litres/min
Time frame: During 6-min walk test with each oxygen delivery device
Lowest SpO2 recorded during the 6-min walk test on each device
Time frame: End 6-min walk test with each oxygen delivery device
The distance walked in 6 minutes with each oxygen delivery device will be compared
Time frame: End 6-min walk test with each oxygen delivery device
Borg dyspnoea score at the end of the 6-min walk test will be compared between devices
Time frame: End 6-min walk test with each oxygen delivery device
Borg fatigue score at the end of the 6-min walk test will be compared between devices
Time frame: Prior to 6-min walk test with each oxygen delivery device
PaO2 at rest breathing oxygen from each of the two devices will be compared
Time frame: During 6-min walk test on each oxygen delivery device
Proportion of participants who desaturate to less than 80% with each oxygen delivery device will be compared
Anne Holland
Other
Effective Delivery of Ambulatory Oxygen in Interstitial Lung Disease - a Crossover Trial.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07712952
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Seoul, South Korea
View Trial DetailsNCT00678821
Cardiovascular Diseases, Hypertension
Bethesda, Maryland, United States
View Trial DetailsNCT05810493
Interstitial Lung Disease, Lung Diseases
Nice, France
View Trial DetailsNCT05776225
Cardiovascular Diseases, Hypertension
Phoenix, Arizona, United States
View Trial Details